F. Hoffmann-La Roche Ltd: Roche to present data across broad

First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue

Related Keywords

Japan , Kenya , United States , Canada , South Korea , Russia , Switzerland , America , American , Nathalie Meetz , Levi Garraway , Karl Mahler , Sabine Borngr , Gerard Tobin , Bruno Eschli , Birgit Masjost , Loren Kalm , Impact Of Administration Ocrelizumab , Sclerosis Care Center , Genentech , Drug Administration , Head Of Global Product Development , Risdiplam Clinical Trial Development Program , European Union , Roche Group , American Academy Of Neurology , European Medicines Agency , Roche Group Media Relations , American Academy , Annual Meeting , Chief Medical Officer , Global Product , Suboptimal Response , Prior Disease Modifying Therapies , Year Data , Year Interim Results , Term Suppression , Regional Volume Loss , Label Extension , Confirmed Disability Progressions Analyses , Open Label Extensions , Disease Progression , Post Hoc Analyses , Baseline Disease Characteristics , Hispanic Patients , Multiple Sclerosis Enrolled , Patterns Among Newly Diagnosed Patients , Multiple Sclerosis , Secondary Progressive Multiple Sclerosis , Assess Efficacy , Cognition Outcomes , Cellular Responses , Disease Modifying Therapies , Prospective Study , Home Infusion , Patient Reported Outcomes , Outcome Measures , Open Label Rollover Study , Subcutaneous Gantenerumab Long Term Safety , Clinical Trials , Early Alzheimer , Aging And Dementia , Clinical Aspects , Cognitive Impairments , Concept Study , Preliminary Clinical Validity , Remote Smartphone Based Self Assessments , Remote Assessments , Spinal Muscular , On Site Child , Preliminary Efficacy , Safety Data , Risdiplam Treated Infants , Child Neurology , Exploratory Efficacy Data , Spinal Muscular Atrophy , Receiving Treatment , Risdiplam Treatment , Pediatric Patients , Neuromyelitis Optica Spectrum , Term Safety , Neuromyelitis Optica Spectrum Disorder , Open Label Extension Periods , Autoimmune Neurology , Term Efficacy , Results From The Open Label Extension Periods , Open Label Study , Satralizumab Investigating Novel Imaging , Clinical Outcomes , Duchenne Muscular Dystrophy , Year Safety , Functional Outcomes , Trial Evaluating , Treating Patients , Orphan Drug Designation , Breakthrough Therapy Designation , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Hoffmann , Oche , Present , Data , Cross , Road , Impactful , Neuroscience , Portfolio , 022 , Nnual , Meeting ,